Physical Compatibility and Chemical Stability of a Concentrated Solution of Atropine Sulfate (2 mg/mL) for Use as an Antidote in Nerve Agent Casualties
Author(s): Donnelly Ronald F, Corman Celine
Issue: Nov/Dec 2008 - Arthritis and Immunological Diseases
View All Articles in Issue
Page(s): 550-552
Download in electronic PDF format for $75
Abstract: Atropine is one of the preferred antidotes for nerve gas exposure. Effective
therapy requires large doses. Stockpiling of atropine in forms currently available
commercially can be costly and can require a large storage area. Other problems
in using the commercial product are the time required to break the large
number of ampules needed for treatment, and the large volume of medication
that must be administered. A preparation of concentrated atropine for injection
from atropine powder is the ideal solution, but the stability of this preparation is
unknown. A formulation for concentrated atropine sulfate solution (2 mg/mL)
was developed using pharmaceutical-grade powder. The solution was prepared
in isotonic saline solution and packaged in polypropylene syringes, which were
sealed with syringe caps. Assessment of physical stability under several storage
conditions was based on clarity, color, and pH monitoring. Chemical stability of
the preparation was determined by using a stability-indicating high-performance
liquid chromatographic method. All solutions remained clear and colorless,
and the pH changed only slightly over the study period. The potency of the
atropine sulfate solution remained above the United States Pharmacopeia limit
of 93% for the duration of the study. The solutions were physically compatible
and chemically stable when stored for 28 days at 35°C and exposed to light,
364 days at 23°C and exposed to light, or 364 days at 5°C and protected from
light. Concentrated solutions of atropine sulfate can be compounded quickly
and easily by using commercially available pharmaceutical-grade powder as the
active ingredient. The extended shelf-life allows the preparation to be readily
available in the field as required.
Related Keywords:
Celine Corman, MSc, BSc, stability, compatibility, atropine sulfate, concentrated solution, antidote, nerve agents, David E. Shields, PhD, Jennifer Aclan, BSc
Related Articles from IJPC |
Title/Author
(Click for Abstract / Details / Purchase) |
Issue/Page
View/Buy |
Physical Compatibility and Chemical Stability of a Concentrated Solution of Atropine Sulfate (2 mg/mL) for Use as an Antidote in Nerve Agent Casualties
Donnelly Ronald F, Corman Celine
|
Nov/Dec 2008
Pg. 550-552
|
Compounding in the Pharmacy Curriculum: Beyond the Basics
Hinkle Amanda R, Newton Gail D
|
May/Jun 2004
Pg. 181-185
|
Compatibility and Stability of Potassium Chloride and Magnesium Sulfate in 0.9% Sodium Chloride Injection and 5% Dextrose Injection Solutions
Quay Irene, Tan Edward
|
Jul/Aug 2001
Pg. 323-324
|
Basics of Compounding for Disorders of the External Ear
Allen Loyd V Jr
|
Jan/Feb 2004
Pg. 46-48
|
Physical and Chemical Stability of Low and High Concentrations of Morphine Sulfate with Clonidine Hydrochloride Packaged in Plastic Syringes
Xu Quanyun A, Trissel Lawrence A, Pham Lien
|
Jan/Feb 2002
Pg. 66-69
|
Physical and Chemical Stability of Low and High Concentrations of Morphine Sulfate with Bupivacaine Hydrochloride Packaged in Plastic Syringes
Trissel Lawrence A, Xu Quanyun A, Pham Lien
|
Jan/Feb 2002
Pg. 70-73
|
Compatibility and Stability of Linezolid Injection Admixed with Gentamicin Sulfate and Tobramycin Sulfate
Xu Quanyun A, Trissel Lawrence A, Zhang Yanping, Williams Kimberly Y
|
Nov/Dec 2000
Pg. 476-479
|
Physicochemical Stability and Compatibility of Revefenacin (LAMA) and Formoterol Fumarate (LABA) Inhalation Solution Admixture
Ngim Kenley, Patel Jalpa
|
May/Jun 2020
Pg. 242-245
|
Atropine Sulfate 1% Ophthalmic Solution
Allen Loyd V Jr
|
May/Jun 2015
Pg. 242
|
Physical Compatibility of Medications Used in Critically Ill Patients with Balanced Fluid Solutions
Wilder Alyson G, Foushee Jaime A, Fox Laura M, Navalle Jordan, Wright Adrienne M, Greer Megan A
|
May/Jun 2020
Pg. 238-241
|
Atropine Sulfate 0.1 mg/mL in SyrSpend SF pH4 Oral Suspension
Allen Loyd V Jr
|
Sep/Oct 2021
Pg. 412
|
Compatibility Screening of Bivalirudin During Simulated Y-Site Administration with Other Drugs
Trissel Lawrence A, Saenz Christopher
|
Jul/Aug 2002
Pg. 311-315
|
Long-term Physiochemical Stability of Concentrated Solutions of Salbutamol (Albuterol) in Polypropylene Syringes for Use in the Intensive Care Unit and in Obstetrics
Lardinois Benjamin, Baltzis Alexandre, Delcave Charlotte, Soumoy Laura, Jamart Jacques, Bihin Benoît, Hecq Jean-Daniel, Galanti Laurence
|
Sep/Oct 2019
Pg. 434-437
|
Morphine Sulfate 16-mg and Atropine Sulfate 0.4-mg/mL Injection
Allen Loyd V Jr
|
Sep/Oct 2005
Pg. 394
|
Investigation of the Physical, Chemical, and Microbiological Stability of Oral Solutions Compounded with Herbals
Khokhlova Kateryna O, Zdoryk Oleksandr A
|
May/Jun 2018
Pg. 240-246
|
Stability of Alprazolam, Atropine Sulfate, Glutamine, Levofloxacin, Metoprolol Tartrate, Nitrofurantoin, Ondansetron Hydrochloride, Oxandrolone, Pregabaline, and Riboflavin in SyrSpend SF pH4 Oral Suspensions
de Oliveira Ferreira Anderson, Polonini Hudson C, Loures da Silva Sharlene, Cerqueira de Melo Victor Augusto, de Andrade Laura, Fernandes Brandão Marcos Antônio
|
May/Jun 2017
Pg. 255-263
|
Meperidine HCl 100-mg/mL and Atropine Sulfate 0.4-mg/mL Injection
Allen Loyd V Jr
|
Jul/Aug 2003
Pg. 300
|
Physical and Chemical Stability of Morphine Sulfate 5-mg/mL and 50-mg/mL Packaged in Plastic Syringes
Trissel Lawrence A, Xu Quanyun A, Pham Lien
|
Jan/Feb 2002
Pg. 62-65
|
Wetting and/or Solubilizing Agents, Featured Excipient:
Allen Loyd V Jr
|
Jul/Aug 2001
Pg. 310-312
|
Chemical and Physical Compatibility of an Intravenous Solution of Epinephrine with Calcium Chloride
Weeks Phillip A, Teng Yang, Wu Lei, Sun Mary, Yang Zhen, Chow Diana S-L
|
Mar/Apr 2014
Pg. 152-158
|
Return to Top |